🇺🇸 FDA
Pipeline program

BGB-16673

BGB-16673-302

Phase 3 small_molecule active

Quick answer

BGB-16673 for CLL is a Phase 3 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
CLL
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials